With the pandemic disrupting the healthcare system, how has workers’ comp been impacted?
With the pandemic disrupting the healthcare system, how has workers’ comp been impacted?
Data from 26,000 claims finds that early physical therapy reduces costs and disability duration.
A wide-sweeping order on national telehealth policy requires federal agencies to begin making plans for change.
Data from nearly 12,000 COVID-19 claims breaks down coverage among industries, telemedicine insights, and more.
2020 has been a year of disruption, and we want to know what the industry thinks about COVID-19, telehealth, opioids, AI, and more!
The FDA recommends healthcare professionals co-prescribe the opioid overdose reversal drug with all opioid prescriptions.
Healthesystems’ VP of Clinical Services addresses COVID-19 disruptions to workers’ comp, along with helpful strategies
AMA hopes to shift from a crisis-reaction framework to a more holistic model that prevents overdose while helping pain patients receive care.
Beyond first responders and healthcare workers, essential workers including grocery store workers are now covered by workers’ comp.
With cases increasing as individuals return to work, injured workers face barriers to care, risk of infection, and more.
As complex claims continue to impact workers’ comp, our new article in WorkCompWire addresses the need for early warnings and clinical guidance.
Subcutaneous injections of the new biologic, adalimumab-fkjp, were approved for seven indications.
Strategies for anticipating and mitigating complex claim risks.
The AMA suggests that prescription medications are no longer a significant factor in the opioid epidemic, and that opioid prescription limits should change.
Arkansas and Louisiana enacted policies to protect businesses from civil liability stemming from COVID-19 exposure.
Data from 28 states years found that NSAIDs and dermatological agents are seeing growth in spending.
With opioid utilization decreasing, what concerns do other pain therapies pose?
With data from 36 states across 12 years, this report highlights the differences in prices paid for medical services across the nation.
Occupations are divided into risk categories where each category must utilize appropriate face coverings, masks, or respirators.
The National Safety Council discusses managing employee anxiety stemming from COVID-19 when returning to work.
Elyxyb (celecoxib) is an NSAID for the acute treatment of migraine with or without aura.
How comorbidities, fatigue, and mental health impact claims management.
The FDA allows emergency use in response to positive trials, but more research is needed.
A new study explores patients’ use of health services, the impact on medicine use, research activity, and more.
Many states expanded workers’ comp for COVID-19, but California casts a wider net.
New developments with diagnostic testing and the use of chloroquine and hydroxychloroquine.
Healthesystems’ AVP of Advocacy & Compliance discusses regulatory action related to COVID-19 with WorkCompWire.
The FDA, JAMA, and others think blood from those who recovered from COVID-19 could benefit those with the illness.
With frontline workers at risk, states are expanding coverage to healthcare workers, first responders, and other frontline workers.
Healthesystems’ VP of Clinical Services discusses population trends, non-opioid pain therapies, and comorbidities with WorkCompWire.
Healthesystems has created a developments webpage to track updates impacting workers’ comp.
Anjeso and a new Advil formulation target pain, while Nurtec™ and Vyepti™ target migraines.
Healthesystems collaborated with Risk & Insurance to survey 669 workers’ comp professionals on top trends and challenges.
A study of 41,000 adults finds that only treatment with buprenorphine or methadone reduced risk of overdose.
Several state workers’ comp programs are relaxing telehealth rules to promote social distancing.
Healthesystems’ AVP of Advocacy & Compliance discusses industry challenges, special initiatives, and more in a video spotlight.
A new seizure drug has been approved, and a nerve growth drug advances in clinical trials.
What will 2020 hold for marijuana acceptance, employee misclassification, formularies, and AI?
An analysis of 1.5 million claims found early physical therapy lowers odds of opioid use by 14%.
Testing positive for marijuana use could one day no longer prohibit employment.
With a flurry of opioid developments lately, what does the big picture look like?
Migraine, arthritis, and insomnia drug approvals, and a gabapentinoids safety warning.
Does the active ingredient in magic mushrooms have a future in mental health?
Phase 3 studies are underway, and current research sees potential for MDMA in psychotherapy.
A recent meta-analysis of over 100 trials and studies found lavender to significantly reduce anxiety levels.
A biosimilar to Humira is approved, the FDA Fast Tracks a PTSD drug, and more.
Understand how prices are set for medical equipment and services, and how to scrutinize those costs.
According to the CWCI, reduced opioid utilization from 2010-2017 saved $6.5 billion in California comp costs.
Beyond compensability, Minnesota considers rules for evaluation, treatment planning, acceptable psychotherapies, and more.
Workers’ comp publications cover Healthesystems content surrounding aging physicians, successful return-to-work programs, and more.
A previous gastrointestinal drug recall expands, while a new recall for an anxiety drug is issued.
The guideline covers a wide range of relevant topics, including pain, dosing, dangerous co-prescribing, comorbidities, and more.
Shortly after California made strides on employee classification for gig economy jobs, New Jersey and New York have taken action.
The Society of Actuaries published a report that claims the economic burden of the opioid epidemic was $631 billion from 2015-2018.
Indicated for various gastrointestinal concerns, these recalls could impact certain workers’ comp patients.
PwC explores how social factors impact chronic health conditions.
This reclassification will entitle millions of workers to benefits previously withheld, including workers’ comp.
Join Healthesystems at booth #1922, at an educational presentation, or by taking our industry survey with Risk & Insurance.
NKTR-181 (loxicodegol) was to receive an approval decision by August 29th, but a reevaluation of opioid policy has resulted in a delay.
Healthesystems’ clinical leaders speak to mitigation strategies to reduce workplace injuries stemming from fatigue.
